Intrathecal and intracerebroventricular dopamine for Parkinson's disease

Abstract

While CDD directly to the CSF can provide a constant delivery of the dopaminergic drug resulting in a more stable treatment effect without the limitations of traditional oral therapy without peripheral effects, it is still young and longitudinal data is lacking. These experimental therapies show promise and further investigation into their efficacy and safety could extend the frontiers for management of PD.

Keywords: Continuous dopamine delivery; Intracerebroventricular; Intrathecal; Levodopa; Parkinson’s disease.